To the Editor We have concerns about the recently published Original Investigation by Kitahara and colleagues.1 Radioactive iodine (RAI) is an effective and safe therapy that has been used in the treatment of hyperthyroidism for more than 78 years.2-4 Unfortunately, Kitahara and colleagues1 report an increased risk of solid tumor development, which leads referring clinicians and patients to question a safe and effective treatment, namely RAI, for alternative therapies. In this letter, we outline our concerns with the article and recommend careful evaluation of the article data before any changes in patient management are made.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Peacock JG, Clemenshaw MN, Banks KP. Safety of the Use of Radioactive Iodine in Patients With Hyperthyroidism. JAMA Intern Med. 2019;179(12):1737–1738. doi:https://doi.org/10.1001/jamainternmed.2019.5117
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: